Back to search

Onyx Scientific Limited

03947634

active
Private Limited Company
england wales
Companies House
Health Score
70 / 100

Some Concerns

30/30
Filing
0/30
Financial
40/40
Risk
  • Loss before tax (-10)
  • Current liabilities exceed current assets (-10)
  • Going concern doubt noted in accounts (-10)

Details

UNITS 97 & 98 SILVERBRIAR, SUNDERLAND, SR5 2TQ
Incorporated 14/03/2000

Compliance

Last accounts

31/03/2025

medium

Next accounts due

31/12/2026

On track

Confirmation statement

Last: 14/03/2026

Due 28/03/2027

On track

Industry

21100
Manufacture of basic pharmaceutical products

Officers

Jonathan Charles Christian Atherton

director · Since 21/05/2025

British

Richard William Chubb

director · Since 21/05/2025

British

Pranaya Godha

director · Since 08/08/2011

Indian

Nathan Vincent Lane

director · Since 05/07/2007

British

Julian Northen

director · Since 21/05/2025

British

Former

Anthony Flinn

secretary · Resigned 08/08/2011

London Law Secretarial Limited

corporate nominee secretary · Resigned 28/03/2000

Stephen Andrew Bone

director · Resigned 29/07/2003

Denise Bowser

director · Resigned 31/05/2024

Alan Robert Clark

director · Resigned 05/07/2007

Anthony Flinn

director · Resigned 28/03/2012

John Neil Harrison

director · Resigned 05/07/2007

Ajit Kumar Jain

director · Resigned 30/03/2015

Ashok Kumar

director · Resigned 30/03/2015

Derek John Londesbrough

director · Resigned 12/06/2025

Vineet Luhariwala

director · Resigned 31/07/2013

Julian Northen

director · Resigned 30/05/2025

London Law Services Limited

corporate nominee director · Resigned 28/03/2000

CompanyRankvs 100+ SIC 21100 peers
79

Financial strength97th percentile among SIC peers · 24/25
Employees99th percentile among SIC peers · 15/15
LiquidityCurrent ratio 5.72× · 20/20
Longevity15 years trading (max 15) · 15/15
Filing complianceAll filings up to date · 15/15
Going concern doubt -10
Show leaderboard
How is this score calculated?
Financial strength24/25 pts

Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.

Employees15/15 pts

Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.

Liquidity20/20 pts

Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.

Longevity15/15 pts

One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.

Filing compliance15/15 pts

Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.

Risk deductions

Going concern doubt: -10 pts

Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.

Going Concern Doubt

we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the directors with respect to going co

Key FinancialsYear ending 31/03/2025

Turnover

£10.9M

Annual revenue

Net Worth

£9.2M

Balance sheet strength

Cash

£2.5M

Cash in the bank

Profit Before Tax

-£252k

Bottom line earnings

Net Current Assets

£4.2M

Working capital

Current Assets

£5.1M

Current Liabilities

£889k

Fixed Assets

£5.8M

Debtors

£2.4M

Cost of Sales

£6.1M

Gross Profit

£4.8M

Admin Expenses

£5.1M

Operating Profit

-£286k

Profit After Tax

-£237k

118avg. employees+2

Tax at Year End

Dividends paid£1.0M

People Costs

Wages & salaries£4.0M
NI contributions£386k

Balance Sheet

Assets less current liabilities£10.0M
Prepared with IRIS Accounts Production

EstimatesDerived

YearCurrent RatioImplied Profit
20255.72-£1.2M
20243.08

Derived from filed accounts. Not audited figures.